References
- Guiducci S, Giacomelli R, Matucci-Cerinic M. Vascular complications of scleroderma. Autoimmun Rev 2007;6:520–23.
- Sunderkotter C, Herrgott I, Bruckner C. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009;160:835–43.
- Wigley FM, Seibold JR, Wisc RA. Intravenous iloprost treatment of Raynaud’s phenomenon for ischaemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407–13.
- Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, . EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620–8.
- Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, . Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985–93.
- De La Vega A, Derk CT. Phosphodiesterase-5 inhibitors for the treatment of Raynaud’s: a novel indication. Expert Opin Invest Drug 2009;18:23–9.
- Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980–5.
- Pakodzi A, Howell K, Black CM. Addition of the short-term phosphodiesterase-5 inhibitor sildenafil to iloprost therapy for scleroderma digital vasculopathy. Arthritis Rheum 2007;56(Suppl):825.
- Brueckner C, Becker MO, Kroencke T, Huscher D, Scherer HU, Worm M, . Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010;69:1475–8.
- Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Mistra R, . Efficacy of tadalafil in secondary Raynaud’s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology 2010;49:2420–8.